Selinexor

{{Short description|Anti-cancer drug}} {{cs1 config|name-list-style=vanc|display-authors=6}} {{Use dmy dates|date=November 2022}} {{Infobox drug | drug_name = | INN = | type =  | image = Selinexor.svg | image_class = skin-invert-image | width = | alt = Skeletal formula of selinexor | caption =

| pronounce = {{IPAc-en|ˌ|s|ɛ|l|ɪ|ˈ|n|ɛ|k|s|ɔːr}}<br />{{respell|SEL|i|NEKS|or}} | tradename = Xpovio, Nexpovio | Drugs.com = {{drugs.com|monograph|selinexor}} | MedlinePlus = a619044 | DailyMedID = Selinexor | pregnancy_AU = D | pregnancy_AU_comment = <ref name="Xpovio APMDS" /><ref>{{cite web | title = Updates to the Prescribing Medicines in Pregnancy database | date = 21 December 2022 | website = Therapeutic Goods Administration (TGA) | url = https://www.tga.gov.au/resources/resource/guidance/updates-prescribing-medicines-pregnancy-database | access-date = 2 January 2023 }}</ref> | pregnancy_category= Use should be avoided | routes_of_administration = By mouth | class = | ATCvet = | ATC_prefix = L01 | ATC_suffix = XX66 | ATC_supplemental =

| legal_AU = S4 | legal_AU_comment = <ref name="Xpovio APMDS">{{cite web | title = Xpovio APMDS | date = 24 March 2022 | website = Therapeutic Goods Administration (TGA) | url = https://www.tga.gov.au/resources/auspmd/xpovio | access-date = 4 April 2022 }}</ref> | legal_BR =  | legal_BR_comment = | legal_CA = Rx-only | legal_CA_comment = <ref>{{cite web | title = Summary Basis of Decision - Xpovio | date = 23 October 2014 | website = Health Canada | url = https://hpr-rps.hres.ca/reg-content/summary-basis-decision-detailTwo.php?linkID=SBD00608&lang=en | access-date = 28 November 2022 }}</ref><ref>{{cite web | title = Product monograph | url = https://pdf.hres.ca/dpd_pm/00066090.PDF | website = hres.ca | access-date = 24 March 2024 }}</ref> | legal_DE =  | legal_DE_comment = | legal_NZ =  | legal_NZ_comment = | legal_UK =  | legal_UK_comment = | legal_US = Rx-only | legal_US_comment = <ref name="Xpovio FDA label" /> | legal_EU = Rx-only | legal_EU_comment = <ref name="Nexpovio EPAR">{{cite web | title = Nexpovio EPAR | date = 25 January 2021 | website = European Medicines Agency (EMA) | url = https://www.ema.europa.eu/en/medicines/human/EPAR/nexpovio | access-date = 27 May 2021 | archive-date = 2 June 2021 | archive-url = https://web.archive.org/web/20210602135035/https://www.ema.europa.eu/en/medicines/human/EPAR/nexpovio | url-status = live }} Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.</ref><ref>{{cite web | title = Nexpovio Product information | website = Union Register of medicinal products | url = https://ec.europa.eu/health/documents/community-register/html/h1537.htm | access-date = 3 March 2023 }}</ref> | legal_UN =  | legal_UN_comment = | legal_status =

| IUPAC_name = (2''Z'')-3-{3-[3,5-Bis(trifluoromethyl)phenyl]-1,2,4-triazol-1-yl}-''N''′-pyrazin-2-ylprop-2-enehydrazide | C=17|H=11|F=6|N=7|O=1 | SMILES = C1=CN=C(C=N1)NNC(=O)/C=C\N2C=NC(=N2)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F | StdInChI = | StdInChI_comment = | StdInChIKey = | density = | density_notes = | melting_point = | melting_high = | melting_notes = | boiling_point = | boiling_notes = | solubility = | sol_units = | specific_rotation = }}

'''Selinexor''' sold under the brand name '''Xpovio''' among others, is a selective inhibitor of nuclear export used as an anti-cancer medication. It works by blocking the action of exportin 1<ref name="Nexpovio EPAR" /> and thus blocking the transport of several proteins involved in cancer-cell growth from the cell nucleus to the cytoplasm, which ultimately arrests the cell cycle and leads to apoptosis.<ref name="Fung_2014">{{cite journal | vauthors = Fung HY, Chook YM | title = Atomic basis of CRM1-cargo recognition, release and inhibition | journal = Seminars in Cancer Biology | volume = 27 | pages = 52–61 | date = August 2014 | pmid = 24631835 | pmc = 4108548 | doi = 10.1016/j.semcancer.2014.03.002 }}</ref> It is the first drug with this mechanism of action.<ref name="Gandhi_2018" /><ref name="Feuerstein_2019">{{cite news | vauthors = Feuerstein A | title = FDA approves new multiple myeloma drug despite toxicity concerns | date = 3 July 2019 | url = https://www.statnews.com/2019/07/03/fda-approves-new-multiple-myeloma-drug-despite-toxicity-concerns/ | work = STAT | access-date = 6 July 2019 | archive-date = 25 September 2020 | archive-url = https://web.archive.org/web/20200925222627/https://www.statnews.com/2019/07/03/fda-approves-new-multiple-myeloma-drug-despite-toxicity-concerns/ | url-status = live }}</ref>

The most common side effects include nausea (feeling sick), vomiting, decreased appetite, weight loss, diarrhea, tiredness, thrombocytopenia (low blood-platelet counts), anaemia (low red-blood cell counts), low levels of white blood cells and hyponatraemia (low blood sodium levels).<ref name="Nexpovio EPAR" />

Selinexor was granted accelerated approval by the U.S. Food and Drug Administration (FDA) in July 2019, for use in combination with the corticosteroid dexamethasone for the treatment of adults with relapsed refractory multiple myeloma (RRMM) who have received at least four prior therapies and whose disease is resistant to several other forms of treatment, including at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody.<ref name="FDA PR">{{cite press release | title = FDA approves new treatment for refractory multiple myeloma | date = 3 July 2019 | website = U.S. Food and Drug Administration (FDA) | url = https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-refractory-multiple-myeloma | archive-url = https://web.archive.org/web/20191120193252/https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-refractory-multiple-myeloma | archive-date = 20 November 2019 | url-status = dead | access-date = 20 November 2019 }} {{PD-notice}}</ref> In December 2020, selinexor was approved by the FDA in combination with bortezomib and dexamethasone for the treatment of adults with multiple myeloma who have received at least one prior therapy.<ref name="cite164368af">{{Cite web | title = Karyopharm Announces FDA Approval of XPOVIO® (Selinexor) as a Treatment for Patients with Multiple Myeloma After at Least One Prior Therapy | url = https://investors.karyopharm.com/2020-12-18-Karyopharm-Announces-FDA-Approval-of-XPOVIO-R-Selinexor-as-a-Treatment-for-Patients-with-Multiple-Myeloma-After-At-Least-One-Prior-Therapy | access-date = 21 December 2020 | archive-date = 8 March 2021 | archive-url = https://web.archive.org/web/20210308113830/https://investors.karyopharm.com/2020-12-18-Karyopharm-Announces-FDA-Approval-of-XPOVIO-R-Selinexor-as-a-Treatment-for-Patients-with-Multiple-Myeloma-After-At-Least-One-Prior-Therapy | url-status = live }}</ref> In clinical trials, it was associated with a high incidence of severe side effects, including low platelet counts and low blood sodium levels.<ref name="Feuerstein_2019" /><ref name="Mulcahy_2019">{{cite news | vauthors = Mulcahy N | title = FDA Approves Selinexor for Refractory Multiple Myeloma | date = 3 July 2019 | url = https://www.medscape.com/viewarticle/915213 | work = Medscape | access-date = 6 July 2019 | archive-date = 15 January 2021 | archive-url = https://web.archive.org/web/20210115151515/https://www.medscape.com/viewarticle/915213 | url-status = live }}</ref><ref name="FDA Snapshot">{{cite web | title = Drug Trials Snapshots: Xpovio | date = 16 July 2019 | website = U.S. Food and Drug Administration (FDA) | url = https://www.fda.gov/drugs/drug-trials-snapshots-xpovio | archive-url = https://web.archive.org/web/20191120193816/https://www.fda.gov/drugs/drug-trials-snapshots-xpovio | archive-date = 20 November 2019 | url-status = dead | access-date = 20 November 2019 }} {{PD-notice}}</ref>

The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.<ref>{{cite web | title = New Drug Therapy Approvals 2019 | date = 31 December 2019 | website = U.S. Food and Drug Administration | url = https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/new-drug-therapy-approvals-2019 | access-date = 15 September 2020 | archive-date = 16 September 2020 | archive-url = https://web.archive.org/web/20200916144738/https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/new-drug-therapy-approvals-2019 | url-status = dead }}</ref> Selinexor was approved for medical use in the European Union in March 2021.<ref name="Nexpovio EPAR" />

==Medical uses== Selinexor is approved in combination with bortezomib and dexamethasone for the treatment of adults with multiple myeloma who have received at least one prior therapy.<ref name="cite164368af" /> Selinexor is also approved for use in combination with the steroid dexamethasone in people with relapsed or refractory multiple myeloma who have received at least four prior therapies and whose disease is refractory to at least two proteosome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody (so-called "quad-refractory" or "penta-refractory" myeloma),<ref name="Chim_2018" /> for whom no other treatment options are available.<ref name="Feuerstein_2019" /><ref name="Mulcahy_2019" /> It is the first drug to be approved for this indication.<ref name="Barrett_2019">{{cite news | vauthors = Barrett J | title = New Treatment for Refractory Multiple Myeloma Granted FDA Approval | date = 3 July 2019 | url = https://www.pharmacytimes.com/news/new-treatment-for-refractory-multiple-myeloma-granted-fda-approval | work = Pharmacy Times | access-date = 7 July 2019 | archive-date = 12 August 2020 | archive-url = https://web.archive.org/web/20200812073137/https://www.pharmacytimes.com/news/new-treatment-for-refractory-multiple-myeloma-granted-fda-approval | url-status = live }}</ref>

In June 2020, the U.S. Food and Drug Administration (FDA) approved an additional indication for selinexor to treat adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least two lines of systemic therapy.<ref name="FDA selinexor">{{cite web | title = FDA approves selinexor for relapsed/refractory diffuse large B-cell ly | date = 22 June 2020 | website = U.S. Food and Drug Administration | url = https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-selinexor-relapsedrefractory-diffuse-large-b-cell-lymphoma | access-date = 24 June 2020 | archive-date = 12 August 2020 | archive-url = https://web.archive.org/web/20200812102121/https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-selinexor-relapsedrefractory-diffuse-large-b-cell-lymphoma | url-status = dead }} {{PD-notice}}</ref>

In the European Union, selinexor is indicated in combination with dexamethasone for the treatment of multiple myeloma in adults who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.<ref name="Nexpovio EPAR" /> Selinexor is also ivestigated as a potential therapeutic option in liposarcoma.<ref name="Remiszewski_2025">{{cite journal | vauthors = Remiszewski P, Gaik W, Skora A, Wąż J, Filipek K, Pisklak A, Dudzisz-Śledź M, Rutkowski P, Czarnecka A | title = Selinexor in the treatment of liposarcoma: from preclinical evidence to clinical practice | journal = Medical Oncology | volume = 42 | issue = 4 | article-number = 94 | date = March 2025 | pmid = 40056309 | doi = 10.1007/s12032-025-02651-2 }}</ref>

==Adverse effects== In the clinical study (the BOSTON study) used to support FDA approval in patients with multiple myeloma after at least one prior therapy (once-weekly selinexor in combination with once-weekly bortezomib and dexamethasone), the most common adverse reactions were cytopenias, along with gastrointestinal and constitutional symptoms and were consistent with those previously reported from other selinexor studies. Most adverse reactions were manageable with dose modifications and/or standard supportive care. The most common non-hematologic adverse reactions were fatigue (59%), nausea (50%), decreased appetite (35%), and diarrhea (32%) and were mostly Grade 1 and 2 events. The most common Grade 3 and 4 adverse reactions were thrombocytopenia (43%), lymphopenia (38%), fatigue (28%) and anemia (17%).<ref>{{Cite web | title = XPOVIO (selinexor) tablets, for oral use | work = Karyopharm Therapeutics Inc. | url = https://www.karyopharm.com/wp-content/uploads/2019/07/NDA-212306-SN-0071-Prescribing-Information-01July2019.pdf | access-date = 30 September 2022 | archive-date = 28 July 2021 | archive-url = https://web.archive.org/web/20210728111704/https://www.karyopharm.com/wp-content/uploads/2019/07/NDA-212306-SN-0071-Prescribing-Information-01July2019.pdf | url-status = live }}{{full citation needed|date=December 2020}}</ref>

The most common adverse reactions (incidence ≥20%) in people with diffuse large B-cell lymphoma (DLBCL), excluding laboratory abnormalities, were fatigue, nausea, diarrhea, appetite decrease, weight decrease, constipation, vomiting, and pyrexia.<ref name="FDA selinexor" /> Grade 3-4 laboratory abnormalities in ≥15% were thrombocytopenia, lymphopenia, neutropenia, anemia, and hyponatremia.<ref name="FDA selinexor" /> Serious adverse reactions occurred in 46% of people, most often from infection.<ref name="FDA selinexor" /> Thrombocytopenia was the leading cause of dose modifications.<ref name="FDA selinexor" /> Gastrointestinal toxicity developed in 80% of people and any grade hyponatremia developed in 61%.<ref name="FDA selinexor" /> Central neurological adverse reactions occurred in 25% of people, including dizziness and mental status changes.<ref name="FDA selinexor" />

The prescribing information provides warnings and precautions for thrombocytopenia, neutropenia, gastrointestinal toxicity, hyponatremia, serious infection, neurological toxicity, and embryo-fetal toxicity.<ref name="FDA selinexor" /><ref name="Xpovio FDA label"/>

==Mechanism of action== [[File:RanGTPcycle.png|thumb|upright=1.3|Schematic illustration of the Ran cycle of nuclear transport. Selinexor inhibits this process at the nuclear export receptor (upper right).]]

Like other selective inhibitors of nuclear export (SINEs), selinexor works by binding to exportin 1 (also known as XPO1 or CRM1). XPO1 is a karyopherin which performs nuclear transport of several proteins, including tumor suppressors, oncogenes, and proteins involved in governing cell growth, from the cell nucleus to the cytoplasm; it is often overexpressed and its function misregulated in several types of cancer.<ref name="Fung_2014" /> By inhibiting the XPO1 protein, SINEs lead to a buildup of tumor suppressors in the nucleus of malignant cells and reduce levels of oncogene products which drive cell proliferation.<ref name="Remiszewski_2025" /> This ultimately leads to cell cycle arrest and death of cancer cells by apoptosis.<ref name="Fung_2014" /><ref name="Gandhi_2018" /><ref name="Xpovio FDA label"/> ''In vitro'', this effect appeared to spare normal (non-malignant) cells.<ref name="Fung_2014" /><ref name="Chen_2018">{{cite journal | vauthors = Chen C, Siegel D, Gutierrez M, Jacoby M, Hofmeister CC, Gabrail N, Baz R, Mau-Sorensen M, Berdeja JG, Savona M, Savoie L, Trudel S, Areethamsirikul N, Unger TJ, Rashal T, Hanke T, Kauffman M, Shacham S, Reece D | title = Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom macroglobulinemia | journal = Blood | volume = 131 | issue = 8 | pages = 855–863 | date = February 2018 | pmid = 29203585 | doi = 10.1182/blood-2017-08-797886 | doi-access = free }}</ref>

Inhibiting XPO1 affects many different cells in the body which may explain the incidence of adverse reactions to selinexor.<ref name="Gandhi_2018" /> Thrombocytopenia, for example, is a mechanistic and dose-dependent effect, occurring because selinexor causes a buildup of the transcription factor STAT3 in the nucleus of hematopoietic stem cells, preventing their differentiation into mature megakaryocytes (platelet-producing cells) and thus slowing production of new platelets.<ref name="Gandhi_2018" />

==Chemistry== Selinexor is a fully synthetic small-molecule compound, developed by means of a structure-based drug design process known as induced-fit docking. It binds to a cysteine residue in the nuclear export signal groove of exportin 1. Although this bond is covalent, it is slowly reversible.<ref name="Fung_2014" />

==History== Selinexor was developed by Karyopharm Therapeutics, a pharmaceutical company focused on the development of drugs that target nuclear transport. It was approved in the United States in July 2019,<ref name="FDA approval">{{cite web | title = Drug Approval Package: Xpovio | date = 26 July 2019 | website = U.S. Food and Drug Administration (FDA) | url = https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212306Orig1s000TOC.cfm | access-date = 24 June 2020 | archive-date = 9 April 2021 | archive-url = https://web.archive.org/web/20210409163402/https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212306Orig1s000TOC.cfm | url-status = dead }}</ref><ref name="FDA PR" /><ref>{{cite web | title = Xpovio (selinexor) FDA Approval History | date = 3 July 2019 | website = Drugs.com | url = https://www.drugs.com/history/xpovio.html | access-date = 20 November 2019 | archive-date = 9 July 2019 | archive-url = https://web.archive.org/web/20190709191420/https://www.drugs.com/history/xpovio.html | url-status = live }}</ref> on the basis of a single-arm Phase IIb clinical trial. The FDA decided to grant accelerated approval despite a previous recommendation from an FDA Advisory Committee Panel which had voted 8–5 to delay approving the drug until the results from an ongoing Phase III study were known.<ref name="Feuerstein_2019" />

Selinexor in combination with dexamethasone was granted accelerated approval and was granted orphan drug designation.<ref name="FDA PR" /> The FDA granted the approval of Xpovio to Karyopharm Therapeutics.<ref name="FDA PR" />

Approval was based on SADAL (KCP-330-009; NCT02227251), a multicenter, single-arm, open-label trial in participants with DLBCL after two to five systemic regimens.<ref name="FDA selinexor" /> Participants received selinexor 60 mg orally on days one and three of each week.<ref name="FDA selinexor" />

In December 2020, the FDA expanded selinexor's approved indication to include its combination with bortezomib and dexamethasone for the treatment of adults with multiple myeloma who have received at least one prior therapy.

== Society and culture == === Legal status === On 28 January 2021, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a conditional marketing authorization for the medicinal product Nexpovio intended for the treatment of relapsed and refractory multiple myeloma.<ref name="Nexpovio: Pending EC decision" /> The applicant for this medicinal product is Karyopharm Europe GmbH.<ref name="Nexpovio: Pending EC decision">{{cite web | title = Nexpovio: Pending EC decision | date = 29 January 2021 | website = European Medicines Agency (EMA) | url = https://www.ema.europa.eu/en/medicines/human/summaries-opinion/nexpovio | access-date = 1 February 2021 | archive-date = 1 February 2021 | archive-url = https://web.archive.org/web/20210201205307/https://www.ema.europa.eu/en/medicines/human/summaries-opinion/nexpovio | url-status = live }} Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.</ref> Selinexor was approved for medical use in the European Union in March 2021.<ref name="Nexpovio EPAR" />

==Research== Under the codename KPT-330, selinexor was tested in several preclinical animal models of cancer, including pancreatic cancer, breast cancer, non-small-cell lung cancer, lymphomas, and acute and chronic leukemias.<ref name="Parikh_2014">{{cite journal | vauthors = Parikh K, Cang S, Sekhri A, Liu D | title = Selective inhibitors of nuclear export (SINE)--a novel class of anti-cancer agents | journal = Journal of Hematology & Oncology | volume = 7 | date = October 2014 | pmid = 25316614 | pmc = 4200201 | doi = 10.1186/s13045-014-0078-0 | doi-access = free | article-number = 78 }}</ref> In humans, early clinical trials (phase I) have been conducted in non-Hodgkin lymphoma, blast crisis, and a wide range of advanced or refractory solid tumors, including colon cancer, head and neck cancer, melanoma, ovarian cancer, and prostate cancer.<ref name="Parikh_2014" /> Compassionate use in patients with acute myeloid leukemia has also been reported.<ref name="Parikh_2014" />

The pivotal clinical trial which served to support approval of selinexor for people with relapsed/refractory multiple myeloma was an open-label study of 122 patients known as the STORM trial.<ref name="Xpovio FDA label">{{cite web | title = Xpovio- selinexor tablet, film coated | date = 19 August 2019 | website = DailyMed | url = https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f6dd2682-75a6-4863-90a8-a3197f6f78a8 | access-date = 20 November 2019 | archive-date = 29 August 2021 | archive-url = https://web.archive.org/web/20210829052406/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f6dd2682-75a6-4863-90a8-a3197f6f78a8 | url-status = live }}</ref> In all of the enrolled patients, patients had been treated with a median of seven prior treatment regimens including conventional chemotherapy, targeted therapy with bortezomib, carfilzomib, lenalidomide, pomalidomide, and a monoclonal antibody (daratumumab or isatuximab);<ref name="Chim_2018">{{cite journal | vauthors = Chim CS, Kumar SK, Orlowski RZ, Cook G, Richardson PG, Gertz MA, Giralt S, Mateos MV, Leleu X, Anderson KC | title = Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond | journal = Leukemia | volume = 32 | issue = 2 | pages = 252–262 | date = February 2018 | pmid = 29257139 | pmc = 5808071 | doi = 10.1038/leu.2017.329 }}</ref> nearly all had also undergone hematopoietic stem cell transplantation but had disease that continued to progress.<ref name="Xpovio FDA label"/> The overall response rate was 26%, including two stringent complete responses; 39% of patients had a minimal response or better. The median duration of response was 4.4 months, median progression-free survival was 3.7 months, and median overall survival was 8.6 months.<ref>{{cite journal | vauthors = Chari A, Vogl DT, Gavriatopoulou M, Nooka AK, Yee AJ, Huff CA, Moreau P, Dingli D, Cole C, Lonial S, Dimopoulos M, Stewart AK, Richter J, Vij R, Tuchman S, Raab MS, Weisel KC, Delforge M, Cornell RF, Kaminetzky D, Hoffman JE, Costa LJ, Parker TL, Levy M, Schreder M, Meuleman N, Frenzel L, Mohty M, Choquet S, Schiller G, Comenzo RL, Engelhardt M, Illmer T, Vlummens P, Doyen C, Facon T, Karlin L, Perrot A, Podar K, Kauffman MG, Shacham S, Li L, Tang S, Picklesimer C, Saint-Martin JR, Crochiere M, Chang H, Parekh S, Landesman Y, Shah J, Richardson PG, Jagannath S | title = Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma | journal = The New England Journal of Medicine | volume = 381 | issue = 8 | pages = 727–738 | date = August 2019 | pmid = 31433920 | doi = 10.1056/NEJMoa1903455 | hdl-access = free | doi-access = free | hdl = 2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/302970 }}</ref>

As of 2019, phase I/II and III trials are ongoing,<ref name="Feuerstein_2019" /><ref name="Parikh_2014" /><ref>{{cite web | title = KPT-330 OR Selinexor Clinical Trials | website = ClinicalTrials.gov | url = https://clinicaltrials.gov/search/intervention=KPT-330%20OR%20Selinexor | access-date = 20 November 2019 | archive-date = 29 August 2021 | archive-url = https://web.archive.org/web/20210829052435/https://clinicaltrials.gov/search/intervention=KPT-330%20OR%20Selinexor | url-status = live }}</ref> including the use of selinexor in other cancers and in combinations with other drugs used for multiple myeloma.<ref name="Gandhi_2018">{{cite journal | vauthors = Gandhi UH, Senapedis W, Baloglu E, Unger TJ, Chari A, Vogl D, Cornell RF | title = Clinical Implications of Targeting XPO1-mediated Nuclear Export in Multiple Myeloma | journal = Clinical Lymphoma, Myeloma & Leukemia | volume = 18 | issue = 5 | pages = 335–345 | date = May 2018 | pmid = 29610030 | doi = 10.1016/j.clml.2018.03.003 | doi-access = free }}</ref>

In November 2020, results from the multi-center, Phase III, randomized study (NCT03110562) which evaluated 402 participants with relapsed or refractory multiple myeloma who had received one to three prior lines of therapy were published in The Lancet.<ref name="Grosicki_2020">{{cite journal | vauthors = Grosicki S, Simonova M, Spicka I, Pour L, Kriachok I, Gavriatopoulou M, Pylypenko H, Auner HW, Leleu X, Doronin V, Usenko G, Bahlis NJ, Hajek R, Benjamin R, Dolai TK, Sinha DK, Venner CP, Garg M, Gironella M, Jurczyszyn A, Robak P, Galli M, Wallington-Beddoe C, Radinoff A, Salogub G, Stevens DA, Basu S, Liberati AM, Quach H, Goranova-Marinova VS, Bila J, Katodritou E, Oliynyk H, Korenkova S, Kumar J, Jagannath S, Moreau P, Levy M, White D, Gatt ME, Facon T, Mateos MV, Cavo M, Reece D, Anderson LD, Saint-Martin JR, Jeha J, Joshi AA, Chai Y, Li L, Peddagali V, Arazy M, Shah J, Shacham S, Kauffman MG, Dimopoulos MA, Richardson PG, Delimpasi S | title = Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial | journal = Lancet | volume = 396 | issue = 10262 | pages = 1563–1573 | date = November 2020 | pmid = 33189178 | doi = 10.1016/S0140-6736(20)32292-3 | hdl-access = free | s2cid = 226308726 | hdl = 2436/623569 }}</ref> The study was designed to compare the efficacy, safety and certain health-related quality of life parameters of once-weekly selinexor in combination with once-weekly Velcade® (bortezomib) plus low-dose dexamethasone (SVd) versus twice-weekly Velcade® plus low-dose dexamethasone (Vd). The primary endpoint of the study was progression-free survival (PFS) and key secondary endpoints included overall response rate (ORR), rate of peripheral neuropathy, and others. Additionally, the BOSTON study allowed for patients on the Vd control arm to crossover to the SVd arm following objective (quantitative) progression of disease verified by an Independent Review Committee (IRC). The BOSTON study was conducted at over 150 clinical sites internationally.

Although the study had one of the highest proportions of patients with high-risk cytogenetics (~50%) as compared with other Velcade-based studies in previously treated myeloma, the median PFS in the SVd arm was 13.93 months compared to 9.46 months in the Vd arm, representing a 4.47 month (47%) increase in median PFS (hazard ratio[HR]=0.70; p=0.0075). The SVd group also demonstrated a significantly greater ORR compared to the Vd group (76.4% vs. 62.3%, p=0.0012). Patients who had received only one prior line of therapy also demonstrated a higher ORR on the SVd arm as compared to the Vd arm (80.8% vs. 65.7%, p=0.0082). Importantly, SVd therapy compared to Vd therapy showed consistent PFS benefit and higher ORR across several important subgroups.<ref name="Grosicki_2020"/>

In 2020, selinexor underwent a clinical trial for treatment of COVID-19.<ref>[https://news.lvhn.org/lvhn-among-early-participants-to-test-cancer-drug-as-covid-19-treatment/ LVHN Among Early Participants to Test Cancer Drug as COVID-19 Treatment] {{Webarchive|url=https://web.archive.org/web/20210124055911/https://news.lvhn.org/lvhn-among-early-participants-to-test-cancer-drug-as-covid-19-treatment/ |date=24 January 2021 }}, Lehigh Valley Hospital–Cedar Crest (LVHN) website, 7 May 2020</ref> In this phase 2 randomized placebo-controlled single-blind trial named XPORT-CoV-1001 with a total of 190 participants with severe COVID-19, treatment with selinexor resulted in higher mortality (16% vs. 9%) and more serious adverse events (23% vs. 16%) than placebo.<ref name="XPORT-CoV-1001">{{ClinicalTrialsGov|NCT04349098|Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection (Coronavirus)}}</ref>

== References == {{Reflist}}

== External links == * {{cite web | title = Selinexor | url = https://druginfo.nlm.nih.gov/drugportal/name/selinexor | archive-url = https://web.archive.org/web/20210324180246/https://druginfo.nlm.nih.gov/drugportal/name/Selinexor | url-status = dead | archive-date = 24 March 2021 | publisher = U.S. National Library of Medicine | work = Drug Information Portal }}

Category:Aminopyrazines Category:Antineoplastic drugs Category:Hydrazides Category:Orphan drugs Category:Teratogens Category:Triazoles Category:(Trifluoromethyl)benzene derivatives Category:Biaryls